Document is current
Any future updates will be listed below
-
Authors
Yang, Linda
Chang, Chih-Chuan https://orcid.org/0000-0002-2963-3069
Sun, Zhe
Madsen, Dennis
Zhu, Haisun https://orcid.org/0000-0001-8395-9409
Padkjær, Søren B
Wu, Xiaoai
Huang, Tao
Hultman, Karin
Paulsen, Sarah J
Wang, Jishu
Bugge, Anne https://orcid.org/0000-0001-5885-4541
Frantzen, Jane Boesen
Nørgaard, Per
Jeppesen, Jacob Fuglsbjerg
Yang, Zhiru
Secher, Anna
Chen, Haibin https://orcid.org/0000-0003-2589-7347
Li, Xun
John, Linu Mary
Shan, Bing
He, Zhenhua
Gao, Xiang https://orcid.org/0000-0001-8137-8571
Su, Jing
Hansen, Kristian T
Yang, Wei
Jørgensen, Sebastian Beck https://orcid.org/0000-0002-9648-0971
- License Information
-
More Information
Article History
Received: 18 May 2017
Accepted: 3 August 2017
First Online: 28 August 2017
Competing interests
: All authors are or have been working for Novo Nordisk A/S, a pharmaceutical company producing and selling medicine for the treatment of diabetes and obesity.
